Select Publications | Research To Practice

Submitted by web@researchtop... on Wed, 08/29/2018 - 08:19

Neil Love, MD

Love N et al. A biomarker-driven algorithm for sequencing of systemic therapy for metastatic NSCLC: A survey of 25 investigators. Chicago Multidisciplinary Symposium in Thoracic Oncology 2017;Abstract PS02.17.

Matthew S Davids, MD, MMSc

Byrd JC et al. The Bruton tyrosine kinase (Btk) inhibitor ACP-196: Marked activity in relapsed/refractory CLL with a favorable safety profile. Blood 2015;126(23):831. Abstract

Damle RN et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94(6):1840-7. Abstract

Döhner H et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343(26):1910-6. Abstract

Fischer K et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial. Blood 2016;127(2):208-15. Abstract

Hallek M et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 2010;376(9747):1164-74. Abstract

Hamblin TJ et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94(6):1848-54. Abstract

Landau DA et al. Mutations driving CLL and their evolution in progression and relapse. Nature 2015;526(7574):525-30. Abstract

O’Brien S et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: A 5-year experience. Blood 2018;131(17):1910-9. Abstract

Rasi S et al. Analysis of NOTCH1 mutations in monoclonal B-cell lymphocytosis. Haematologica 2012;97(1):153-4. Abstract

Rossi D et al. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood 2015;126(16):1921-4. Abstract

Rossi D et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood 2014;123(14):2139-47. Abstract

Rossi D et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 2013;121(8):1403-12. Abstract

Thompson PA et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 2016;127(3):303-9. Abstract

Zainuddin N et al. TP53 mutations are infrequent in newly diagnosed chronic lymphocytic leukemia. Leuk Res 2011;35(2):272-4. Abstract

Zenz T et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010;28(29):4473-9. Abstract

Prof John G Gribben, MD, DSc, FMedSci

Burger JA et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 2015;373(25):2425-37. Abstract

Eichhorst B et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): An international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 2016;17(7):928-42. Abstract

Eichhorst B et al. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22(Suppl 6):vi50-vi54. Abstract

Fischer K et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial. Blood 2016;127(2):208-15. Abstract

Goede V et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014;370(12):1101-10. Abstract

Gribben JG. How and when I do allogeneic transplant in CLL. Blood 2018;132(1):31-9. Abstract

Thurmes P et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma 2008;49(1):49-56. Abstract

Jonathan W Friedberg, MD, MMSc

Anderson MA et al. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood 2017;129(25):3362-70. Abstract

Byrd JC et al. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: Updated results from the phase 1/2 ACE-CL-001 study. Blood 2017;130(Suppl 1):498. Abstract

Cheson BD et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 2012;30(23):2820-2. Abstract

Hallek M et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111(12):5446-56. Abstract

Roberts AW et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 2016;374(4):311-22. Abstract

Seymour JF et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2018;378(12):1107-20. Abstract

Thomas J Kipps, MD, PhD

Burger JA et al. Randomized trial of ibrutinib versus ibrutinib plus rituximab (Ib+R) in patients with chronic lymphocytic leukemia (CLL). Blood 2017;130(Suppl 1):427. Abstract

Choi MY et al. Phase I trial: Cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia. Cell Stem Cell 2018;22(6):951-9. Abstract

Choi M et al. Durable and specific inhibition of ROR1 signaling associates with prolonged progression free survival in patients with chronic lymphocytic leukemia treated with cirmtuzumab. Blood 2017;130(Suppl 1):829. Abstract

Flinn I et al. Safety, efficacy and MRD negativity of a combination of venetoclax and obinutuzumab in patients with previously untreated chronic lymphocytic leukemia — Results from a phase 1b study (GP28331). Blood 2017;130(Suppl 1):430. Abstract

Jain N et al. Combined venetoclax and ibrutinib for patients with previously untreated high-risk CLL, and relapsed/refractory CLL: A phase II trial. Blood 2017;130(Suppl 1):429. Abstract

Kipps TJ et al. Chronic lymphocytic leukaemia. Nat Rev Dis Primers 2017;3:16096. Abstract

Malta TM et al. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell 2018;173(2):338-54. Abstract

Michallet A et al. Phase II, multicenter trial, exploring “Chemo-Sparing” strategy associating obinutuzumab+ibrutinib followed by a MRD driven strategy, in previously untreated symptomatic medically fit chronic lymphocytic leukemia patients (CLL): Preliminary results of the induction phase of the Icll-07 Filo study. Blood 2017;130(Suppl 1):497. Abstract

Wierda WG et al. Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL). Proc ASCO 2018;Abstract 7502.

Woyach, J et al. Acalabrutinib with obinutuzumab in relapsed/refractory and treatment-naïve patients with chronic lymphocytic leukemia: The phase 1b/2 ACE-CL-003 study. Blood 2017;130(Suppl 1):432. Abstract

Yu J et al. Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. Leukemia 2017;31(6):1333-9. Abstract